20-F: Ascendis Pharma Inks Revenue Participation Deal with Royalty Pharma for $150 Million

Ascendis Pharma secures $150 million through a revenue participation agreement with Royalty Pharma, focusing on U.S. sales of SKYTROFA.

Summary

• Ascendis Pharma has entered into a revenue participation right purchase and sale agreement with Royalty Pharma Development Funding, LLC, effective as of September 5, 2023.
• Royalty Pharma will provide Ascendis Pharma with $150 million in exchange for the right to receive revenue payments based on 9.15% of Net Sales of SKYTROFA in the U.S. from January 1, 2025.
• The revenue payment term will end when Royalty Pharma receives 1.65 times the purchase price if the date occurs on or before December 31, 2031, or 1.925 times the purchase price.
• The agreement includes various representations, warranties, and covenants for both parties, including diligence requirements for Ascendis Pharma regarding the manufacturing and commercialization of the product.
• Ascendis Pharma retains control over the commercialization and manufacturing of SKYTROFA.
• The agreement includes provisions for confidentiality, indemnification, and termination under certain conditions, such as a change of control of Ascendis Pharma.

Sentiment

Score: 7

Explanation: The document is a standard financial agreement. The sentiment is neutral to slightly positive as it provides Ascendis Pharma with additional capital.

Positives

• Ascendis Pharma gains immediate access to $150 million in funding.
• The structure allows Ascendis Pharma to retain operational control over SKYTROFA.
• The deal provides a non-dilutive financing option compared to equity offerings.
• The agreement supports continued investment in SKYTROFA's commercialization and potential expansion into new indications.

Negatives

• Ascendis Pharma will forgo a portion of future SKYTROFA revenue in the U.S.
• The agreement includes covenants that could restrict Ascendis Pharma's operational flexibility.
• A change of control triggers an immediate buy-out payment to Royalty Pharma.

Risks

• Failure to meet sales targets for SKYTROFA could impact Ascendis Pharma's ability to meet its obligations under the agreement.
• Changes in the market or competition could affect SKYTROFA's sales and, consequently, the revenue payments to Royalty Pharma.
• Disputes over the interpretation or enforcement of the agreement could lead to costly legal proceedings.
• The buy-out payment could become due unexpectedly, straining Ascendis Pharma's finances.

Future Outlook

Ascendis Pharma aims to use the funding to support the commercialization of SKYTROFA and potentially expand its indications.

Industry Context

Revenue interest purchase agreements are a common financing tool in the pharmaceutical industry, allowing companies to monetize future revenue streams to fund current operations and development.

Comparison to Industry Standards

• Royalty Pharma is a well-known investor in pharmaceutical royalties, with a diverse portfolio of revenue streams from various drugs.
• Similar deals include Royalty Pharma's investment in Vertex Pharmaceuticals' cystic fibrosis franchise and Biogen's Tysabri.
• The terms of the Ascendis Pharma deal appear to be within the typical range for royalty financing agreements in the biopharmaceutical sector.

Stakeholder Impact

• Shareholders: May benefit from the increased financial stability and continued commercialization efforts.
• Employees: Job security may be enhanced due to the company's improved financial position.
• Patients: Continued access to SKYTROFA and potential development of new treatments.
• Suppliers: Continued business relationship with Ascendis Pharma.

Next Steps

• Ascendis Pharma will receive the $150 million payment from Royalty Pharma.
• Ascendis Pharma will continue to commercialize SKYTROFA in the U.S.
• Ascendis Pharma will begin making revenue payments to Royalty Pharma starting January 1, 2025.

Key Dates

Keywords

Royalty Pharma, SKYTROFA, Revenue Participation, Ascendis Pharma, Agreement, Commercialization, Financing, Net Sales